Lawrence A Kenyon bought Outlook Therapeutics, Inc. (OTLK) stock

Lawrence A Kenyon, Chief Financial Officer of Outlook Therapeutics, Inc. (OTLK), bought 101,010 shares of OTLK stock, per an SEC Form 4 filed Aug 14, 2026.

The shares came through a private deal, not the open market.

The trade was reported on Aug 14, 2026.

OTLK has moved -9.3% since the trade date, from $0.76 to $0.69 (Sep 21, 2026 close).